VBL Information

View Top Employees from VBL

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL's lead oncology product candidate, ofranergene obadenovec (VB-111), is a targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VBL Therapeutics is headquartered in Israel.

Website	http://www.vblrx.com
Ticker	VBLT
Revenue	$585000
Employees	681 (219 on RocketReach)
Founded	2000
Address	8 Hasatat St, Modi'in, Central District 7178106, IL
Phone	+1 662-928-1022
Fax	+972 8-993-5001
Industry	Food and Beverage Services, Pharmaceuticals, Healthcare
Web Rank	6 Million
Keywords	Cancer Therapies, Oncology, First-In-Class, Cancer Treatment, Biopharmaceutical, Clinical Stage, Drug Development, Molecular Medicine, Cancer Research, Pharmaceutical Research, Biotechnology, Medicine, Healthcare, Immunotherapy, Clinical Trials, Drug Discovery
Competitors	Johnson & Johnson, Roche, Novartis, Pfizer, Bristol Myers Squibb, Genentech, Amgen, Regeneron, Gilead Sciences, Receptos, a wholly-owned subsidiary of Celgene +48 more (view full list)
SIC	SIC Code 28 Companies, SIC Code 80 Companies, SIC Code 283 Companies
NAICS	NAICS Code 3254 Companies, NAICS Code 541 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 54 Companies, NAICS Code 325 Companies